Steel City Dialysis is a medicare approved dialysis facility center in Birmingham, Alabama and it has 10 dialysis stations. It is located in Jefferson county at 1809 Avenue H, Birmingham, AL, 35218. You can reach out to the office of Steel City Dialysis at (205) 785-2972. This dialysis clinic is managed and/or owned by Davita. Steel City Dialysis has the following ownership type - Profit. It was first certified by medicare in September, 2014. The medicare id for this facility is 012646 and it accepts patients under medicare ESRD program.
| Name | Steel City Dialysis |
|---|---|
| Location | 1809 Avenue H, Birmingham, Alabama |
| No. of Dialysis Stations | 10 |
| Medicare ID | 012646 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 1809 Avenue H, Birmingham, Alabama, 35218 | |
| (205) 785-2972 | |
News Archive
Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.
Researchers at Oregon State University recently completed the largest animal study ever done in the field of toxicology, and the findings challenge some basic concepts about how to determine what level of a cancer-causing compound can be considered safe.
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009. Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.
Spine patients afflicted with severe degenerative disc diseases often find diagnostic and treatment options as daunting as the surgery itself. Fortunately, "Getting Back on Their Feet," a new documentary released by the Arthroplasty Patient Foundation, was created specifically to help spine surgery patients overcome obstacles they encounter in their search for wellness.
Anatomy, Modeling and Biomaterial Fabrication for Dental and Maxillofacial Applications provides readers with information about dental implants and biomaterial fabrication for maxillofacial procedures and dental bone / tissue repair.
› Verified 6 days ago
| NPI Number | 1215234992 |
| Organization Name | Steel City Dialysis |
| Doing Business As | Flor Dialysis Llc |
| Address | 1809 Avenue H Ensley, Alabama, 35218 |
| Phone Number | (205) 785-2972 |
News Archive
Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.
Researchers at Oregon State University recently completed the largest animal study ever done in the field of toxicology, and the findings challenge some basic concepts about how to determine what level of a cancer-causing compound can be considered safe.
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009. Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.
Spine patients afflicted with severe degenerative disc diseases often find diagnostic and treatment options as daunting as the surgery itself. Fortunately, "Getting Back on Their Feet," a new documentary released by the Arthroplasty Patient Foundation, was created specifically to help spine surgery patients overcome obstacles they encounter in their search for wellness.
Anatomy, Modeling and Biomaterial Fabrication for Dental and Maxillofacial Applications provides readers with information about dental implants and biomaterial fabrication for maxillofacial procedures and dental bone / tissue repair.
› Verified 6 days ago
| NPI Number | 1558670810 |
| Organization Name | Steel City Dialysis |
| Doing Business As | Renal Treatment Centers- Southeast, Lp |
| Address | 1809 Avenue H Ensley, Alabama, 35218 |
| Phone Number | (205) 785-2972 |
News Archive
Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.
Researchers at Oregon State University recently completed the largest animal study ever done in the field of toxicology, and the findings challenge some basic concepts about how to determine what level of a cancer-causing compound can be considered safe.
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009. Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.
Spine patients afflicted with severe degenerative disc diseases often find diagnostic and treatment options as daunting as the surgery itself. Fortunately, "Getting Back on Their Feet," a new documentary released by the Arthroplasty Patient Foundation, was created specifically to help spine surgery patients overcome obstacles they encounter in their search for wellness.
Anatomy, Modeling and Biomaterial Fabrication for Dental and Maxillofacial Applications provides readers with information about dental implants and biomaterial fabrication for maxillofacial procedures and dental bone / tissue repair.
› Verified 6 days ago
| Dialysis patients with Hemoglobin data | 13 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 15 |
News Archive
Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.
Researchers at Oregon State University recently completed the largest animal study ever done in the field of toxicology, and the findings challenge some basic concepts about how to determine what level of a cancer-causing compound can be considered safe.
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009. Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.
Spine patients afflicted with severe degenerative disc diseases often find diagnostic and treatment options as daunting as the surgery itself. Fortunately, "Getting Back on Their Feet," a new documentary released by the Arthroplasty Patient Foundation, was created specifically to help spine surgery patients overcome obstacles they encounter in their search for wellness.
Anatomy, Modeling and Biomaterial Fabrication for Dental and Maxillofacial Applications provides readers with information about dental implants and biomaterial fabrication for maxillofacial procedures and dental bone / tissue repair.
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 27 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 232 |
| Percentage of adult patients getting regular hemodialysis at the center | 99 |
News Archive
Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.
Researchers at Oregon State University recently completed the largest animal study ever done in the field of toxicology, and the findings challenge some basic concepts about how to determine what level of a cancer-causing compound can be considered safe.
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009. Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.
Spine patients afflicted with severe degenerative disc diseases often find diagnostic and treatment options as daunting as the surgery itself. Fortunately, "Getting Back on Their Feet," a new documentary released by the Arthroplasty Patient Foundation, was created specifically to help spine surgery patients overcome obstacles they encounter in their search for wellness.
Anatomy, Modeling and Biomaterial Fabrication for Dental and Maxillofacial Applications provides readers with information about dental implants and biomaterial fabrication for maxillofacial procedures and dental bone / tissue repair.
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Steel City Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 27 |
| Hypercalcemia patient months | 232 |
| Patients with Serumphosphor | 28 |
| Patients with Serumphosphor less than 3.5 mg/dL | 22 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 20 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 30 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 20 |
| Patients with Serumphosphor greater than 7 mg/dL | 8 |
News Archive
Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.
Researchers at Oregon State University recently completed the largest animal study ever done in the field of toxicology, and the findings challenge some basic concepts about how to determine what level of a cancer-causing compound can be considered safe.
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009. Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.
Spine patients afflicted with severe degenerative disc diseases often find diagnostic and treatment options as daunting as the surgery itself. Fortunately, "Getting Back on Their Feet," a new documentary released by the Arthroplasty Patient Foundation, was created specifically to help spine surgery patients overcome obstacles they encounter in their search for wellness.
Anatomy, Modeling and Biomaterial Fabrication for Dental and Maxillofacial Applications provides readers with information about dental implants and biomaterial fabrication for maxillofacial procedures and dental bone / tissue repair.
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 21 |
| Patient months included in arterial venous fistula and catheter summaries | 180 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 60 |
News Archive
Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.
Researchers at Oregon State University recently completed the largest animal study ever done in the field of toxicology, and the findings challenge some basic concepts about how to determine what level of a cancer-causing compound can be considered safe.
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009. Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.
Spine patients afflicted with severe degenerative disc diseases often find diagnostic and treatment options as daunting as the surgery itself. Fortunately, "Getting Back on Their Feet," a new documentary released by the Arthroplasty Patient Foundation, was created specifically to help spine surgery patients overcome obstacles they encounter in their search for wellness.
Anatomy, Modeling and Biomaterial Fabrication for Dental and Maxillofacial Applications provides readers with information about dental implants and biomaterial fabrication for maxillofacial procedures and dental bone / tissue repair.
› Verified 6 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 26 |
| Hospitalization Rate in facility | 142 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 333.2 |
| Hospitalization Rate: Lower Confidence Limit | 64.8 |
News Archive
Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.
Researchers at Oregon State University recently completed the largest animal study ever done in the field of toxicology, and the findings challenge some basic concepts about how to determine what level of a cancer-causing compound can be considered safe.
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009. Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.
Spine patients afflicted with severe degenerative disc diseases often find diagnostic and treatment options as daunting as the surgery itself. Fortunately, "Getting Back on Their Feet," a new documentary released by the Arthroplasty Patient Foundation, was created specifically to help spine surgery patients overcome obstacles they encounter in their search for wellness.
Anatomy, Modeling and Biomaterial Fabrication for Dental and Maxillofacial Applications provides readers with information about dental implants and biomaterial fabrication for maxillofacial procedures and dental bone / tissue repair.
› Verified 6 days ago
The rate of readmission show you whether patients who were being treated regularly at Steel City Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 18.4 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 39.3 |
| Readmission Rate: Lower Confidence Limit | 5.4 |
News Archive
Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.
Researchers at Oregon State University recently completed the largest animal study ever done in the field of toxicology, and the findings challenge some basic concepts about how to determine what level of a cancer-causing compound can be considered safe.
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009. Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.
Spine patients afflicted with severe degenerative disc diseases often find diagnostic and treatment options as daunting as the surgery itself. Fortunately, "Getting Back on Their Feet," a new documentary released by the Arthroplasty Patient Foundation, was created specifically to help spine surgery patients overcome obstacles they encounter in their search for wellness.
Anatomy, Modeling and Biomaterial Fabrication for Dental and Maxillofacial Applications provides readers with information about dental implants and biomaterial fabrication for maxillofacial procedures and dental bone / tissue repair.
› Verified 6 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Steel City Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| SIR: Upper Confidence Limit | 2.27 |
News Archive
Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.
Researchers at Oregon State University recently completed the largest animal study ever done in the field of toxicology, and the findings challenge some basic concepts about how to determine what level of a cancer-causing compound can be considered safe.
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009. Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.
Spine patients afflicted with severe degenerative disc diseases often find diagnostic and treatment options as daunting as the surgery itself. Fortunately, "Getting Back on Their Feet," a new documentary released by the Arthroplasty Patient Foundation, was created specifically to help spine surgery patients overcome obstacles they encounter in their search for wellness.
Anatomy, Modeling and Biomaterial Fabrication for Dental and Maxillofacial Applications provides readers with information about dental implants and biomaterial fabrication for maxillofacial procedures and dental bone / tissue repair.
› Verified 6 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Steel City Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 24 |
| Transfusion Rate in facility | 23.6 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 181.3 |
| Transfusion Rate: Lower Confidence Limit | 3.9 |
News Archive
Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.
Researchers at Oregon State University recently completed the largest animal study ever done in the field of toxicology, and the findings challenge some basic concepts about how to determine what level of a cancer-causing compound can be considered safe.
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009. Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.
Spine patients afflicted with severe degenerative disc diseases often find diagnostic and treatment options as daunting as the surgery itself. Fortunately, "Getting Back on Their Feet," a new documentary released by the Arthroplasty Patient Foundation, was created specifically to help spine surgery patients overcome obstacles they encounter in their search for wellness.
Anatomy, Modeling and Biomaterial Fabrication for Dental and Maxillofacial Applications provides readers with information about dental implants and biomaterial fabrication for maxillofacial procedures and dental bone / tissue repair.
› Verified 6 days ago
The rate of mortality show you whether patients who were being treated regularly at Steel City Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 143 |
| Mortality Rate in facility | 22.8 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 35.7 |
| Mortality Rate: Lower Confidence Limit | 13.7 |
News Archive
Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.
Researchers at Oregon State University recently completed the largest animal study ever done in the field of toxicology, and the findings challenge some basic concepts about how to determine what level of a cancer-causing compound can be considered safe.
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009. Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.
Spine patients afflicted with severe degenerative disc diseases often find diagnostic and treatment options as daunting as the surgery itself. Fortunately, "Getting Back on Their Feet," a new documentary released by the Arthroplasty Patient Foundation, was created specifically to help spine surgery patients overcome obstacles they encounter in their search for wellness.
Anatomy, Modeling and Biomaterial Fabrication for Dental and Maxillofacial Applications provides readers with information about dental implants and biomaterial fabrication for maxillofacial procedures and dental bone / tissue repair.
› Verified 6 days ago
Birmingham East Dialysis Location: 1105 East Park Drive, Birmingham, Alabama, 35235 Phone: (205) 833-6003 |
News Archive
Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.
Researchers at Oregon State University recently completed the largest animal study ever done in the field of toxicology, and the findings challenge some basic concepts about how to determine what level of a cancer-causing compound can be considered safe.
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009. Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.
Spine patients afflicted with severe degenerative disc diseases often find diagnostic and treatment options as daunting as the surgery itself. Fortunately, "Getting Back on Their Feet," a new documentary released by the Arthroplasty Patient Foundation, was created specifically to help spine surgery patients overcome obstacles they encounter in their search for wellness.
Anatomy, Modeling and Biomaterial Fabrication for Dental and Maxillofacial Applications provides readers with information about dental implants and biomaterial fabrication for maxillofacial procedures and dental bone / tissue repair.
› Verified 6 days ago